Heartflow, Inc.
Heartflow, Inc. develops software-based cardiovascular diagnostics that analyze coronary CT angiography (CCTA) images to help physicians assess coronary artery disease without invasive procedures. Its commercial platform is sold on a usage-driven basis, with core products including Heartflow FFRCT Analysis and Heartflow Plaque Analysis, and it is expanding into workflow tools such as Heartflow RoadMap and the planned PCI Planner.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaAI-enabled coronary physiology analysis used to assess blood flow restriction from CCTA scans.
Coronary plaque assessment product used to support treatment decisions and risk stratification.
RoadMap and planned PCI Planner features that improve workflow efficiency and retention.
Asiakkaat
Heartflow sells primarily to hospitals, health systems, and imaging centers that order analyses for patients being evaluated for coronary artery disease. The company also depends on referring physicians and reading physicians within those accounts, because utilization rises when clinicians adopt the platform as part of routine CAD workups.
Multi-facility systems that buy access across several accounts and drive meaningful case volume.
Facilities that order FFRCT and plaque analyses for routine CAD evaluation.
Cardiologists and other clinicians who choose Heartflow to avoid invasive testing and improve triage.
Government and third-party payors whose coverage and payment policies determine adoption economics.
Strategia
Heartflow is focused on expanding utilization within its installed base while adding new accounts through a scalable, low-capex commercial model. It is also broadening the platform beyond FFRCT into plaque assessment and future PCI planning, aiming to deepen clinical relevance and improve customer retention.
Revenue is usage-driven, so more cases per account directly increase sales.
The product is a long-term growth driver but still early in commercialization.
Adjacent tools can improve retention and make the platform more embedded in care pathways.
Approved markets outside the U.S. provide additional growth without changing the core product.
Maantiede
Q3/2025Heartflow’s commercial base is centered in the United States, where it had more than 1,100 accounts as of December 31, 2024. It also has regulatory approval and commercial presence in the United Kingdom, European Union, Australia, Canada, and Japan, supported by small direct commercial teams in those markets.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Heartflow is highly exposed to reimbursement policy, physician adoption, and customer concentration because most revenue comes from one usage-based product. It also faces technology, regulatory, and competitive risks tied to AI-driven diagnostics, while Plaque Analysis remains early and may not reach expected utilization.
- Dependence on a single core productVaikutus: KorkeaTodennäköisyys: Kohtalainen
Substantially all revenue is generated by Heartflow FFRCT Analysis, making results sensitive to one offering.
Kohdistuu: FFRCT Analysis
- Reimbursement and coverage riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
If payors do not cover the platform or reduce payment amounts, provider adoption can slow materially.
Kohdistuu: Government and third-party payors
- AI and model performance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Incorrect design, poor data, bugs, or cybersecurity issues could impair product performance and create liability.
Kohdistuu: AI algorithms and computational fluid dynamics models
- Plaque Analysis commercialization riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The product is still nascent and may not achieve expected market acceptance or utilization.
Kohdistuu: New product adoption
- Customer concentrationVaikutus: KeskitasoTodennäköisyys: Matala
A small number of large health systems can represent a disproportionate share of revenue.
Kohdistuu: Large health systems and multi-account customers
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized upon delivery of each analysis, so timing of cases affects quarterly results.
Vaikutus: Can create volatility in reported revenue and margins
Case volumes vary with staffing, customer mix, and seasonal physician availability.
Vaikutus: Makes quarter-to-quarter comparisons less comparable
Amortization of these balances flows through cost of revenue and operating expenses over time.
Vaikutus: Affects gross margin and operating leverage
Personnel costs include equity compensation, which can materially affect reported expenses.
Vaikutus: Impacts operating loss and non-cash expense profile
Convertible notes and term loan repayments changed liabilities and financing costs in 2025.
Vaikutus: Affects interest expense, leverage, and cash flow presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
HeartSciences Inc.
HSCSW · Finance Services
HeartBeam, Inc.
BEAT · Surgical & Medical Instruments & Apparatus
Hyperfine, Inc.
HYPR · Electromedical & Electrotherapeutic Apparatus
HeartCore Enterprises, Inc.
HTCR · Services-Computer Processing & Data Preparation
Biotricity Inc.
BTCY · Surgical & Medical Instruments & Apparatus
iRhythm Holdings, Inc.
IRTC · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026